Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing

Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing

Annual-Meeting

1 year
102 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Guillermo Garcia-Manero, MD Of The MD Anderson Cancer Center Discusses Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing.
Up Next Autoplay